Web1 Epidemiology and risk factors Evaluation and initial management Adjuvant chemotherapy for colon cancer Localized rectal cancer Standard cytotoxic chemotherapy for metastatic cancer Tailored chemotherapy strategies Targeting molecular alterations Outline Epidemiology and Risk Factors
Did you know?
WebCirculating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies J Clin Oncol. 2024 Oct 30;36 (35):JCO2024789032. doi: 10.1200/JCO.2024.78.9032. Online ahead of print. Authors Arvind Dasari 1 , Axel Grothey 1 , Scott Kopetz 1 Affiliation WebComprehensive Oncology Review: Colorectal Cancer - Adjuvant Stacey Cohen, MD [email protected]
WebApr 3, 2024 · N Engl J Med 2024 Mar 29 Three months of capecitabine and oxaliplatin therapy was noninferior to 6 months of therapy in patients with lower-risk disease. A standard 6-month course of adjuvant chemotherapy after curative surgery has been … WebOct 1, 2024 · LBA19Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of...
WebJun 1, 2024 · Axel Grothey, MD, a specialist in gastrointestinal cancers, "has decided to leave," the institution told its staff in an email. It's only now, 3 years later, that details have emerged of... WebMar 29, 2024 · Editorial from The New England Journal of Medicine — A New IDEA in Adjuvant Chemotherapy for Colon Cancer ... N Engl J Med 2024; 378:1242-1244 DOI: 10.1056/NEJMe1800419 ... A. Grothey and Others ...
WebJun 3, 2024 · The National Cancer Institute removed Axel Grothey, MD, from his position as co-chair of a steering committee May 27 after reports surfaced that the physician had inappropriate sexual...
WebMay 28, 2024 · Dr. Grothey is one of the leading physicians and researchers. Grothey received a full, unrestricted Tennessee license on March 19, 2024. The findings of fact supporting his licensure include the following: Petitioner was a full professor at Mayo … brush snow off solar panelsWebJan 4, 2024 · NEJM Resident 360 Information, resources, and support needed to approach rotations - and life as a resident. NEJM Healer The most advanced way to teach, practice, and assess clinical reasoning... examples of different level of cas severityWebIDEA: ADVERSE EVENTS 3 vs 6 months NEURO 2 to 6 timeslower DIARRHEA 20% to 30% lower MUCOSITIS 2 timeslower H+F SYN 2 to 3 timeslower! Idea , Grothey, NEJM 2024 examples of different language featuresWebGrothey A, et al. Duration of adjuvant chemotherapy for stage III colon cancer. New England Journal of Medicine. 2024;378:1177. Andre T, et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration: prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX … examples of differentiating contentWebMar 29, 2024 · After the exclusion of persistent DTA mutations, the detection of molecular minimal residual disease was associated with a significantly higher relapse rate than no detection (55.4% vs. 31.9% ... brush snow plowSince 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since oxaliplatin is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health … See more We performed a prospective, preplanned, pooled analysis of six randomized, phase 3 trials that were conducted concurrently to evaluate the noninferiority of adjuvant therapy with either FOLFOX (fluorouracil, leucovorin, and … See more After 3263 events of disease recurrence or death had been reported in 12,834 patients, the noninferiority of 3 months of treatment versus 6 … See more Among patients with stage III colon cancer receiving adjuvant therapy with FOLFOX or CAPOX, noninferiority of 3 months of therapy, as compared with 6 months, was not confirmed in the overall population. However, in patients … See more brush soap warhammerWebAmong patients with cancers that were classified as T4, N2, or both, the disease-free survival rate for a 6-month duration of therapy was superior to that for a 3-month duration (64.4% vs. 62.7%) for the combined treatments (hazard ratio, 1.12; 95% CI, 1.03 to 1.23; … brush soap for acrylic painting